StockWatch
·
Healthcare Research- Analytics & Technology
Clinical Trial16 Nov 2026, 12:21 pm

Suven Life Sciences to Present Alzheimer's Drug Data at CTAD Conference

AI Summary

Suven Life Sciences announced it will present data on two investigational drug candidates, Masupirdine (SUVN-502) and Tenaclidine (SUVN-I6107), at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Boston, USA. The presentations will cover the "Masupirdine Phase-3 Baseline Demographic & Clinical Characteristics" and "Tenaclidine Phase-1 First-In-Human Safety, Tolerability, Pharmacokinetics." The Masupirdine presentation will detail baseline characteristics of patients in the global Phase-3 study for agitation in Alzheimer's patients, with topline results expected in Q2-2027. The Tenaclidine presentation will cover outcomes from Phase-1 studies in healthy subjects. The company highlighted progress in developing therapies for CNS disorders, including Alzheimer's disease.

Key Highlights

  • Suven Life Sciences to present Phase-3 Masupirdine and Phase-1 Tenaclidine data.
  • Presentations at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) Conference.
  • Masupirdine topline results for agitation in Alzheimer's patients expected Q2-2027.
  • Tenaclidine Phase-1 safety, tolerability, and pharmacokinetic data to be shared.
  • Focus on developing innovative therapies for central nervous system (CNS) disorders.